A Phase 4 interventional study of Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg and Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg in Gastrointestinal Ulcer Haemorrhage and Bacterial Infection Due to Helicobacter Pylori (H. Pylori), sponsored by University of Nottingham. Completed at 6 sites in United Kingdom. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2022-05-17.
Sponsored by University of Nottingham · Phase 4, Interventional, and Treatment
HEAT (Helicobacter Eradication Aspirin Trial) is a large simple double-blind placebo controlled outcomes study of Helicobacter pylori (H. pylori) eradication to prevent ulcer bleeding in aspirin users. It will be run by the University of Nottingham, with recruiting centres across the UK. This trial is funded by the National Institute of Health Research Health Technology Assessment (NIHR HTA) Programme.
Aspirin use is widespread and increasing in elderly patients. The main hazard is gastrointestinal bleeding, which may be increasing because of increasing aspirin use. This trial is based on evidence that peptic ulcer bleeding in aspirin users occurs predominantly in H. pylori positive people.
Patients will be identified by their GPs, then asked to attend an appointment with a Research Nurse to consent to the trial and take a H. pylori breath test. Those with a positive result will be randomised to receive a one week course of either eradication treatment or placebo. No follow-up visits are required, but instead information will be extracted from the patients' electronic medical record using the MiQuest search tool.
The trial will continue until 87 adjudicated events (hospitalisation because of definite or probable peptic ulcer bleeding) have occurred, which would occur after a mean 2.5 patient years of follow-up, if trial assumptions are correct.
BACKGROUND: Aspirin use is widespread and increasing in elderly patients. The main hazard is gastrointestinal bleeding, the incidence of which is rising, probably because of increased aspirin use. The proposed trial is based on evidence that peptic ulcer bleeding in aspirin users occurs predominantly in people infected with the ulcerogenic bacterium, Helicobacter pylori. Our hypothesis is that low doses of aspirin do not cause ulcers in the way that high doses do. Instead we think that H. pylori causes the ulcer and aspirin, by thinning the blood, makes it bleed. If the bacterium is eradicated the patient will not get an ulcer and therefore there is no increased bleeding risk with aspirin. Development of the trial protocol has been based on results of a preparatory Medical Research Council-funded 2525 patient pilot study which had a 47% patient response rate. This enabled us to design the currently proposed large simple outcomes study to investigate directly the hypothesis that a one week course of H. pylori eradication will halve the rate of hospitalisation due to ulcer bleeding over \~2.5 years in aspirin users.
TRIAL CONDUCT: A large number of patients (\~170,000), using aspirin \<326 mg daily will be invited to participate. Suitable respondents (\~33,000) who are H. pylori positive (\~6,600) will give consent (including access to Hospital Episode Statistics and Office of National Statistics mortality data) and be randomised to eradication treatment or placebo. There will be no follow-up trial visits for 90% of patients. Instead the MiQuest tool, developed to interrogate different GP electronic databases, will be used together with direct patient notification to identify all possible ulcer bleeding admissions. An expert panel will use validated methodology to adjudicate whether patients have suffered ulcer bleeding (primary endpoint). The trial will continue until 87 positively adjudicated events have occurred, to ensure it has the power to answer the question of whether H. pylori eradication reduces the risk of ulcer bleeding.
658 studies on the registry are indexed under Bacterial Infections; 100 are open to participants now.
This study's enrollment of 30,024 is above the median of 84 across 405 interventional studies indexed under Bacterial Infections.
Browse Bacterial Infections studies →University of Nottingham is the lead sponsor of 455 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Active treatment will consist of seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg
Placebos to seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
Drug: Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
All three medications will be taken orally, twice daily, for seven days.
Also known as: Lansoprazole (CAS: 103577-45-3); 30mg capsules., Clarithromycin (CAS: 81103-11-9); 500mg tablets., Metronidazole (CAS: 99616-64-5) 400mg tablets.
Medication to be taken orally, twice a day, for seven days.
The rate of hospitalisation due to peptic ulcer bleeding in patients who enter the randomised study (only the first event per patient will be analysed), adjudicated by a blinded Committee as definite or probable.
Time frame: 4 years
Other causes of gastrointestinal bleeding (adjudicated); these are predicted not to be affected by H. pylori eradication and will act as a specificity control.
Time frame: 4 years
Cardiovascular outcomes (APTC (Anti Platelet Trialists Collaboration) endpoint, myocardial infarction and stroke, unadjudicated); these are predicted not to be affected.
Time frame: 4 years
The incidence of detected uncomplicated ulcers.
Time frame: 4 years
Ulcer site (Duodenal Ulcer vs. Gastric Ulcer).
Time frame: 4 years
GP-recorded and patient-reported dyspepsia.
Time frame: 4 years
Need for proton pump inhibitor prescription or other antiulcer/dyspepsia medication.
Time frame: 4 years
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Nottingham